You are here

Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Coronary Artery Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
30 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Able to understand and sign an informed consent form.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women who are of childbearing potential.

- Very low likelihood of coronary artery disease (by American Heart Association and
American College of Cardiology standards).

- Documented history of acute myocardial infarction within 30 days.

- Percutaneous coronary intervention or coronary bypass graft surgery within 3 years,
unless typical or atypical anginal symptoms are present.

- Reactive airway disease or other contraindication that preclude a patient from
receiving adenosine.

- Previous heart transplant or listed to receive a heart transplant.

- Cardiomyopathy (idiopathic dilated, restrictive, hypertrophic).

- History of hemodynamically significant supraventricular tachycardia or sustained
ventricular tachycardia.

- Presence of second- or third-degree AV block (in the absence of permanent pacemaker).

- Left ventricular ejection fraction greater than 35%, known prior to the first imaging
procedure.

- Presence of advanced heart failure, New York Heart Association Class IV.

- History of vasospastic/Prinzmetal angina.

- Active (under treatment) cancer (except skin cancers).

- Inability to discontinue antianginal medications, Aggrenox®, dipyridamole, and
xanthine-containing drugs and foods (including caffeine) as required prior to each
imaging procedure.

- Previous participation in a study of binodenoson.

- Any physical or psychosocial condition that, based on the Investigator's judgment,
would prevent the patient from completing the study.

NCT00944294
Pfizer
Completed
Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hypercholesterolemia Coronary Artery Disease
NCT02565615
All Genders
18+
Years
Multiple Sites
Coronary Artery Disease
NCT00944294
All Genders
Coronary Artery Disease
NCT00944970
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now